PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. (Q53076908)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Mikaël M Martino

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Armando Stano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

André J van der Vlies

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Melody A Swartz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Eleonora Simeoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

19 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

804-812

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21094269%20AND%20SRC:MED&resulttype=core&format=json

Vaccines: past, present and future

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Immunization without needles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Recent advances in mucosal vaccines and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Materials engineering for immunomodulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Oxidation-sensitive polymeric nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

7 January 2021

Tissue sulfhydryl groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Comparison of murine nasal-associated lymphoid tissue and Peyer's patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole Range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Stealth PLA-PEG nanoparticles as protein carriers for nasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Identification of a Sequence in Human Toll-like Receptor 5 Required for the Binding of Gram-negative Flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010

Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.010